Literature DB >> 1884735

Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin.

T Lind1, C Cederberg, M Olausson, L Olbe.   

Abstract

The effect of omeprazole on acid secretion and gastrin levels has been investigated in 10 elderly duodenal ulcer patients in remission. Doses of 5, 10, 20 and 40 mg omeprazole were given once daily for 7 consecutive days and the basal (BAO) and peak (PAO) acid output and fasting plasma gastrin concentration were measured 24 h after the seventh dose. Omeprazole suppressed PAO significantly and dose-dependently after doses of 10, 20 and 40 mg, the suppression being 42%, 75% and 85%, respectively. No patient showed complete inhibition of PAO and at least 20 mg had to be given to obtain a marked inhibitory effect in all patients. Increasing the dose to 40 mg had only a slight additional effect compared to 20 mg. There was a relationship between degree of acid inhibition and the increase in fasting plasma gastrin. PAO had to be suppressed by more than 80% before a moderate increase in fasting plasma gastrin was observed. The optimal once-daily oral dose of omeprazole for inhibition of acid secretion in elderly patients appears to be 20 mg. Omeprazole 20-40 mg may cause a moderate increase in fasting plasma gastrin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1884735     DOI: 10.1007/bf00279969

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

Review 1.  The achlorhydria-carcinoid sequence: role of gastrin.

Authors:  W Creutzfeldt
Journal:  Digestion       Date:  1988       Impact factor: 3.216

2.  Inhibition of basal and betazole- and sham-feeding-induced acid secretion by omeprazole in man.

Authors:  T Lind; C Cederberg; G Ekenved; L Olbe
Journal:  Scand J Gastroenterol       Date:  1986-10       Impact factor: 2.423

3.  Biliary excretion of intravenous [14C] omeprazole in humans.

Authors:  T Lind; T Andersson; I Skånberg; L Olbe
Journal:  Clin Pharmacol Ther       Date:  1987-11       Impact factor: 6.875

4.  Acid response to pentagastrin in relation to age and body stature in male and female ulcer patients.

Authors:  S Borgström; S Emås; B Lilja; I Borg
Journal:  Scand J Gastroenterol       Date:  1973       Impact factor: 2.423

5.  Twenty-four-hour intragastric acidity and plasma gastrin concentration in healthy subjects and patients with duodenal or gastric ulcer, or pernicious anaemia.

Authors:  S Lanzon-Miller; R E Pounder; M R Hamilton; N A Chronos; S Ball; J E Mercieca; M Olausson; C Cederberg
Journal:  Aliment Pharmacol Ther       Date:  1987-06       Impact factor: 8.171

6.  Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.

Authors:  C B Lambers; T Lind; S Moberg; J B Jansen; L Olbe
Journal:  N Engl J Med       Date:  1984-03-22       Impact factor: 91.245

7.  Pharmacokinetics of [14C]omeprazole in patients with impaired renal function.

Authors:  J Naesdal; T Andersson; G Bodemar; R Larsson; C G Regårdh; I Skånberg; A Walan
Journal:  Clin Pharmacol Ther       Date:  1986-09       Impact factor: 6.875

8.  Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

Authors:  E C Klinkenberg-Knol; J M Jansen; H P Festen; S G Meuwissen; C B Lamers
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

9.  Acid inhibitory characteristics of omeprazole in man.

Authors:  C Cederberg; G Ekenved; T Lind; L Olbe
Journal:  Scand J Gastroenterol Suppl       Date:  1985

10.  Effect of intermittent weekend therapy with omeprazole on basal and bombesin- and pentagastrin-stimulated gastric acid and serum gastrin.

Authors:  L F Crobach; J B Jansen; C B Lamers
Journal:  Scand J Gastroenterol       Date:  1988-05       Impact factor: 2.423

View more
  8 in total

1.  Pharmacokinetic study of omeprazole in elderly healthy volunteers.

Authors:  S Landahl; T Andersson; M Larsson; B Lernfeldt; P Lundborg; C G Regårdh; E Sixt; I Skånberg
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.

Authors:  L B Barradell; D McTavish
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

Review 3.  Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists.

Authors:  M Lazzaroni; G Bianchi Porro
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

Review 4.  Postsurgical complications in older patients. The role of pharmacological intervention.

Authors:  G Zuccalà; A Cocchi; G Gambassi; R Bernabei; P Carbonin
Journal:  Drugs Aging       Date:  1994-12       Impact factor: 3.923

5.  Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH-feedback-controlled and fixed-dose infusions.

Authors:  C H Wilder-Smith; H U Bettschen; H S Merki
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

Review 6.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 7.  Prescribing policy for antiulcer treatment in the elderly.

Authors:  G Bianchi Porro; M Lazzaroni
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

Review 8.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.